On June 5, 2026, President Cyril Ramaphosa announced South Africa's national rollout of lenacapavir at a stadium in Secunda, Mpumalanga, before thousands of attendees. The drug from US company Gilead Sciences provides HIV protection with two injections per year, eliminating the need for daily pills. South Africa became the first country worldwide to deploy lenacapavir through its public health system: initially in 360 clinics across six provinces and 24 high-risk districts, with the goal of reaching one million people by end of 2027.
7.5 Million Infected: South Africa's HIV Crisis in Numbers
No country has more people living with HIV than South Africa: approximately 7.5 million according to UNAIDS 2024 estimates. Despite years of intervention, new infection rates remain persistently high, especially among young women aged 15 to 24. The most common prevention method, oral pre-exposure prophylaxis (PrEP) based on tenofovir-emtricitabin, was recommended by WHO in 2015 and has reached millions of South Africans. The problem is not efficacy: those taking the daily pill are well protected. The problem is real life. According to an implementation study among young women in South Africa and Zimbabwe, 55 percent experienced gaps in medication adherence within twelve months; only 21 to 22 percent maintained consistent adherence after six months.
What the PURPOSE Trials Demonstrated
Lenacapavir works as a capsid inhibitor that blocks a critical step in HIV replication and is deposited as a depot under the skin. A single injection provides protection for six months. In PURPOSE-1, conducted among approximately 5,300 women and girls in South Africa and Uganda, zero participants in the lenacapavir arm contracted HIV: 100 percent efficacy. The result was so clear that the trial was stopped early to offer access to the control group. In PURPOSE-2, which included cisgender men, transgender women, and non-binary individuals, efficacy reached 99.9 percent. South Africa's health regulator SAHPRA approved lenacapavir on October 27, 2025, becoming the first regulatory authority on the African continent to do so, eight months before the official rollout.
Price: $60 instead of $28,000
Lenacapavir costs approximately $28,000 per person per year in the United States. South Africa pays $60, according to South African health magazine Bhekisisa, made possible through subsidy from the Children's Investment Fund, which covers the difference. Generic versions are expected by 2027 at approximately $40 per person per year, potentially eliminating the need for subsidies. Health Minister Aaron Motsoaledi emphasized the goal of making lenacapavir a public good: accessible, affordable, and locally produced. South Africa has already submitted an application for manufacturing rights.
The rollout is deliberately structured independently of US development aid. Ramaphosa noted at the launch that the program is supported by South African government funds, the Children's Investment Fund, and partnerships with Unitaid and the Wits Reproductive Health and HIV Institute. Given massive cuts to the US PEPFAR program under the current US administration, this autonomy is notable.
In Context: What Long-Acting Injections Achieve in Practice
The predecessor drug cabotegravir shows what injectable HIV protection means in practice. The HPTN-084 trial compared two options among over 3,200 women in sub-Saharan Africa: cabotegravir injections every eight weeks versus daily Truvada. The HIV infection rate in the injection group was 0.21 percent at study end; in the pill group, 1.79 percent. The more than eightfold difference was not pharmacological: in clinical trials where all medication was taken consistently, oral PrEP is similarly effective. The effect emerges because injectable preparations reduce the compliance burden from thousands of daily decisions to just a few clinic visits per year.
For perspective on how far HIV prevention has traveled in three decades: in the early 1990s, HIV-positive patients took multiple daily pills with significant side effects. By 2016, a single daily pill sufficed. In 2022, the first complete HIV treatment as an injection every two months was approved (Cabenuva). Lenacapavir now represents the next frontier on the prevention side: protection consisting of two injections per year.
One Million People to Be Protected by End of 2027
The WHO explicitly praised South Africa on June 15, 2026, as a global pioneer. No other country currently deploys lenacapavir through public health systems. Yet Ramaphosa cautioned at the launch that the injection is no miracle cure. It does not protect against other sexually transmitted infections, requires regular clinic visits, and must remain part of a comprehensive HIV program. Parallel to South Africa's launch, Brazil began early distribution through the Unitaid partnership with Wits RHI, becoming one of the first countries to do so.
The goal is ambitious: one million people by end of 2027, three million by 2029. Whether South Africa can build the logistical and financial infrastructure to embed lenacapavir across all 24 high-risk districts will determine in the coming two years whether this program becomes the global standard for HIV prevention with long-acting injections.